Celldex Therapeutics, Inc. (CLDX)

Nasdaq Stock Exchange
USD
US15117B2025
26 March 1990  –  2 December 2022

Performance

Annualized Return
-8.9%
Sharpe Ratio
0.33
Maximum Drawdown
-99.95%

Metrics

Metric Celldex Therapeutics, Inc.
Initial Balance $10,000
Final Balance $475
Returns   [View more details]
Month-To-Date 0.67%
Year-To-Date -3.36%
3M 22.83%
6M 64.06%
Annual Return (3Y) 143.07%
Annual Return (5Y) -3.08%
Annual Return (All) -8.9%
Risk   [View more details]
Annual Volatility 87.68%
Max Drawdown -99.95%
Sharpe Ratio 0.33
Sortino Ratio 0.52
Adjusted Sortino (S/√2) 0.37

  • Initial balance: The amount of starting capital used to invest in the asset or portfolio. In this case, we're starting with a $10,000 investment on March 1990.
  • Final balance: The amount of capital we've accrued over time as of December 2022.
  • Annual return: Also known as annualized return, or CAGR (Compound Annual Growth Rate), measures how much an investment has increased on average each year, during a specific time period. The time period in this case is approximately 33 year(s). Even a small difference in return can have a big impact on the final balance over a long period of time.
  • Annual volatility: Basically indicates how much, in percentage points, the investment can deviate from its annual return, under most circumstances. An investment with an annual return of 5% and an annual volatility of 10% would indicate returns from approximately -5% to 15% most of the time. A lower volatility is usually preferred to ensure more steady returns over time.
  • Best year: The best performance attained over its lifetime in a given year.
  • Worst year: The worst performance undergone over its lifetime in a given year.
  • Max drawdown: The largest percentage drop from a peak to a trough of an asset or portfolio, before a new peak is attained. Maximum drawdown is an indicator of downside risk over a specified time period.
  • Sharpe Ratio: The Sharpe ratio measures the performance of an investment compared to a risk-free asset, after adjusting for its risk. A Sharpe Ratio above 1 is considered good.
  • Sortino Ratio: The Sortino Ratio is a variation of the Sharpe ratio that only penalizes the investment for negative volatility/outcomes, and not for positive volatility. A Sortino Ratio above 1 is considered good.
  • Adjusted Sortino Ratio: Sortino Ratio/√2. To allow for comparing the Sortino ratio to the Sharpe ratio, we multiply the risk measure of the Sortino ratio by the square root of 2 (which is the same as dividing the Sortino ratio by the square root of 2).
  • Ulcer Index: The Ulcer Index (UI) is a technical indicator that measures downside risk in terms of both the depth and duration of price declines.
  • Gain to Pain Ratio: The sum of all returns divided by the absolute value of the sum of all negative returns. In essence, the GPR shows the ratio of net returns to the losses incurred in getting those returns.

Annualized Returns

Annual Return 1y Annual Return 3y Annual Return 5y Annual Return 10y Annual Return 20y Annual Return
Celldex Therapeutics, Inc. 3.46% 143.07% -3.08% -8.66% -8.4% -8.9%

Annual Returns

Year Celldex Therapeutics, Inc.
1990 -32.72%
1991 274.15%
1992 -33%
1993 5.16%
1994 -67.74%
1995 24.8%
1996 -48.08%
1997 50.62%
1998 -28.28%
1999 41.14%
2000 178.14%
2001 -41.63%
2002 -71.82%
2003 142.48%
2004 -26.64%
2005 -6.47%
2006 -28.72%
2007 -62.69%
2008 32%
2009 -41.04%
2010 -11.78%
2011 -36.89%
2012 158.08%
2013 260.8%
2014 -24.62%
2015 -14.08%
2016 -77.42%
2017 -19.77%
2018 -93.03%
2019 -24.88%
2020 685.65%
2021 120.55%
2022 -3.36%

Celldex Therapeutics, Inc. had 12 positive years and 21 negative years. That's a positive ratio of 36%.

Monthly Returns

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YTD
1990 0% 0% 0% -14.2% 0% 3.2% 12.9% -28.6% -8% -0% 13.2% -9.5% -23.3%
1991 44.6% 14.6% 51.3% -11.8% -9.7% -12.8% 34.2% -9% 32% 31.8% -4.6% 6.1% 162.5%
1992 18.2% -26% -9% -21.5% 7.3% -8.4% 14.8% -12.9% -5.6% 2% 15.4% -1.7% -19.9%
1993 -13.6% -13.7% 11.3% -17.3% 28.5% -0% 13.4% -6.8% -7.3% 17.7% -0% 3.3% 23.2%
1994 -14.6% -18.9% -23.3% -0% -6.1% -3.1% -20% 16.7% -14.3% -0% -12.7% -4.6% -77.5%
1995 40% -14.3% -6.3% 46.6% -0% -18.2% 27.9% 13% -7.6% -22.2% -3.7% -7.4% 57.1%
1996 -0% -5.8% -6.5% 4.4% 34.8% 0% -38.8% -2.5% 0% -13.4% -6.5% -13.4% -33.6%
1997 15.4% 1.1% -17.5% 1.9% -5.7% 24.7% -19.8% 44% -1.9% 17.9% -5.2% 3% 101.4%
1998 -10.2% -8.7% 47% 34% -22.3% -18.3% -0% -27.6% -24.3% -10.9% 2.5% 40% 24%
1999 19.4% -28.2% 4% -5.8% -15% 69.6% 29.7% -9.1% -15.2% 3.3% 11.4% 1.2% 101.7%
2000 122.7% 101.1% -14.1% -27.7% -27.2% 111.2% -38.4% 49.1% 11.6% -21.9% -5.9% -13.5% 182.3%
2001 16.2% -33.5% -18.8% 15.1% -3.6% 18.2% -3.7% -35.1% -32.9% 43.5% 12.9% 4.4% 4.9%
2002 -19.5% -58.5% 29.1% 2.3% -38.4% 2.8% -11.6% 13.1% -1.8% 27.3% 5.7% -23.6% -39.4%
2003 3.5% -6.8% 1.8% 15.3% 81.3% 24.6% -15.9% -3.3% 2.6% -4.1% 13.9% 4.2% 118%
2004 33.9% -28.9% 0% 6.9% -12.9% 9.5% -24.8% -9% -6% 9.4% -1.1% 8.6% -7.3%
2005 -10% -7.2% -3% -25.2% 16.4% -17.6% 14.5% -2.2% -0.8% 5.4% 30.7% 5% 16.7%
2006 5.9% -1% 27.4% -29.1% -6.2% -3.6% -5.6% -3.3% -10.9% 12.2% 0.7% -9.5% -13.4%
2007 2.2% 4.4% 2.1% -19.9% -14.5% -17% -21.7% -18.5% 5.7% 5.4% -18.6% 4.2% -66.7%
2008 28% 7.8% 18.4% 11.5% 28.2% 3.9% 11.5% -14.8% -15.9% -33.4% -16.3% 22% 89.1%
2009 -6.2% -7.7% -5.1% 33% 4.2% -13.3% -2.8% -24.5% -4.4% -20.6% 3.7% 3.3% -19.3%
2010 -4.5% 15.2% 19.5% 33.1% -17.9% -32% 12.5% -15.6% -7.6% 11.3% -6.7% -0.7% 10.7%
2011 -10.2% 6.5% 2% 6% -14.3% -2.7% 1.1% -13.1% -26.8% 40.5% -17.1% -2.3% -23.3%
2012 82.3% -20% 34.3% -10.4% -8.6% 24.1% -0.1% 9.1% 11.7% -12.5% 7.8% 13% 111.8%
2013 11.2% 27.6% 21.6% 12.7% -2% 22.1% 31.2% 6.1% 63.1% -35.4% 21.2% -12.8% 148.9%
2014 6.5% 13.3% -39.5% -15.1% -2.6% 11.7% -19.8% 21.5% -18.5% 29.2% 21.1% -10% 6.6%
2015 17.4% 19.2% 9.1% -13.9% 20.3% -12.6% -6.6% -37% -29% 14.4% 49.3% -12.9% 7.3%
2016 -47.1% -18.1% -44.4% 5.8% 14.5% -4.1% 5.2% -28.1% 21.7% -22% 21% -7.1% -97.2%
2017 -7.9% 8.6% 2% -7.8% -15% -12.7% -7.3% 7.4% 16.3% -14.7% 23% -5.3% -10.3%
2018 -2.8% -18.5% 3.6% -68.2% -21.6% -13.2% -7.7% 8% -10.2% -30.3% -5.1% -33.7% -210.1%
2019 156.6% -30.2% -7.5% -25.6% -16.9% -11.8% -18.7% -2.8% 0.5% 5.2% 7.1% -7.1% 14%
2020 3.8% 13.6% -36.9% 47.6% 9% 386.9% -20.8% 16% 24.2% 6.8% 42% -22.1% 287.4%
2021 23.4% 25.3% -23.9% 47.2% -7.8% 19.6% 30.8% 20.3% 2.5% -21.2% -10.4% 1.4% 100.8%
2022 -19.7% -3.6% 13.9% -10.3% -23% 14.6% 13.9% -1% -7.5% 25% 5.6% 0.7% 18%
Pos 59.4% 40.6% 57.6% 48.5% 31.3% 48.5% 42.4% 36.4% 36.4% 54.5% 57.6% 45.5% 60.6%
Avg 15.2% -2.8% 1.3% -0% -1.5% 16.5% -0.9% -2.4% -2% 1.4% 5.9% -2.3% 28.6%

Other Return Metrics

Metric Celldex Therapeutics, Inc.
Cumulative Return -95.25%
Enh Ann Return 18.91%
Best Year 685.65%
Worst Year -93.03%
Best Month 386.89%
Worst Month -68.24%
Best Day 82.4%
Worst Day -64.67%
Win Ratio (Yearly) 36.36%
Win Ratio (Quarterly) 48.48%
Win Ratio (Monthly) 46.56%
Win Ratio (Daily) 47.46%

Annual Volatility

Annual Volatility 1y Annual Volatility 3y Annual Volatility 5y Annual Volatility 10y Annual Volatility 20y Annual Volatility
Celldex Therapeutics, Inc. 67.77% 98.1% 95.02% 85.17% 80.88% 87.68%

Sharpe Ratio

Sharpe Ratio 1y Sharpe Ratio 3y Sharpe Ratio 5y Sharpe Ratio 10y Sharpe Ratio 20y Sharpe Ratio
Celldex Therapeutics, Inc. 0.39 1.33 0.44 0.33 0.3 0.33

3-Year Rolling Sharpe Ratio

The rolling Sharpe Ratio gives a clue about the continued consistency or stability of the risk-adjusted returns.

Drawdown Periods

Simply said, a drawdown is the "pain" period experienced by an investor between a peak (new highs) and subsequent valley (a low point before moving higher). In the table below are the fifth largest drawdowns encountered for the portfolio/asset in question.

Celldex Therapeutics, Inc.

start valley end Drawdown days
2000-03-07 2020-03-20 - -99.95% 8305
1992-01-24 1998-10-20 2000-03-02 -92.43% 2960
1990-07-16 1990-08-24 1991-03-08 -48.83% 235
1991-04-18 1991-06-24 1991-09-27 -40.02% 162
1991-11-13 1991-12-24 1992-01-22 -30.04% 70

The Celldex Therapeutics, Inc. took approximately 78 months on average to recover from a major drawdown. The longest drawdown lasted 277 months.

Underwater plot

The underwater plot shows you the drawdown periods on a chart. Whereas the performance chart usually gives you a positive viewpoint, the underwater plot gives you a pessimistic viewpoint. It helps you to visualize downtrends that occurred and how long it took for the portfolio's value to rebound to hit a new high after suffering a loss.

Other Risk Metrics

Metric Celldex Therapeutics, Inc.
Sharpe Ratio 0.33
Sortino Ratio 0.52
Adjusted Sortino (S/√2) 0.37
Calmar Ratio -0.09
Omega Ratio -0.09
Gain to Pain Ratio 0.07
Winckel Ratio 42.42
Ulcer Index 0.86
Kelly Criterion 2.9%
Skew 1.11
Kurtosis 19.69
End of: